Archita Biswas, Manuela Salvucci, Kate Connor, Heiko Düssmann, Steven Carberry, Michael Fichtner, Ellen King, Brona Murphy, Alice C O'Farrell, Jane Cryan, Alan Beausang, Josephine Heffernan, Mattia Cremona, Bryan T Hennessy, James Clerkin, Kieron J Sweeney, Steve MacNally, Francesca Brett, Philip O'Halloran, Orna Bacon, Simon Furney, Maite Verreault, Emie Quissac, Franck Bielle, Mohammed H Ahmed, Ahmed Idbaih, Sieger Leenstra, Ioannis Ntafoulis, Federica Fabro, Martine Lamfers, Anna Golebiewska, Frank Hertel, Simone P Niclou, Romain Tching Chi Yen, Andreas Kremer, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Diether Lambrechts, Manasa Kalya Purushothama, Alexander Kel, Annette T Byrne, Jochen H M Prehn
BACKGROUND: Glioblastoma (GBM) is an aggressive brain cancer that typically results in death in the first 15 months after diagnosis. There have been limited advances in finding new treatments for GBM. In this study, we investigated molecular differences between patients with extremely short (≤ 9 months, Short term survivors, STS) and long survival (≥ 36 months, Long term survivors, LTS). METHODS: Patients were selected from an in-house cohort (GLIOTRAIN-cohort), using defined inclusion criteria (Karnofsky score > 70; age < 70 years old; Stupp protocol as first line treatment, IDH wild type), and a multi-omic analysis of LTS and STS GBM samples was performed...
May 26, 2023: Journal of Neuro-oncology